Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

HC Wainwright issued their Q1 2025 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat forecasts that ...

CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th.

Jazz recently received approval for Rylaze in Europe and a new cancer drug Ziihera, which should boost oncology drug sales. JAZZ has an impressive long-term expected earnings growth rate of 7.4%.

With the market getting increasingly fickle on external shocks, investors are more focused on finding an investment strategy that emphasizes judging a stock's inherent potential. Needless to say, ...

With the market getting increasingly fickle on external shocks, investors are more focused on finding an investment strategy that emphasizes judging a stock's inherent potential. Needless to say ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, March 10, 2025. Let’s take ...

In 2025, seniors will pay less for 64 medications if they get them through Medicare Part B, which covers outpatient care, ...